We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Celldex Therapeutics Inc | NASDAQ:CLDX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.64 | 4.01% | 42.50 | 42.00 | 96.25 | 42.98 | 41.34 | 41.91 | 605,345 | 05:00:01 |
“Celldex has made considerable progress on an important strategic prioritization of our pipeline, following announcement in April of the METRIC study results in triple-negative breast cancer and discontinuation of the glembatumumab program across all indications,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “In 2018, we will focus primarily on continued clinical development of two company-sponsored programs—CDX-1140, a promising CD40 agonist, and CDX-3379, which blocks ErbB3, a receptor thought to play an important role in regulating cancer cell growth and survival. Development of varlilumab and CDX-301 will also continue externally through investigator-sponsored initiatives and internally through inclusion in combination studies.”
“In line with this, to extend our financial resources and direct them to the advancement of the programs we believe can bring the most value to both patients and shareholders, we made significant cuts to our business operations, including executing a corporate restructuring in late April. Based on our progress to date, we believe our cash on hand combined with proceeds from our established ATM will support the continued development of our pipeline through 2020. This extended runway will provide for multiple inflection points, and we are solely focused on executing along these lines.”
Pipeline Prioritization:
Celldex is focusing its efforts and resources on the continued research and development of:
To conserve resources, Celldex is discontinuing development of:
Recent Program Highlights Presented at the American Association for Cancer Research (AACR) 2018 Annual Meeting in April
First Quarter 2018 Financial Highlights and Updated 2018 Guidance
Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2018 were $123.2 million compared to $139.4 million as of December 31, 2017. The decrease was primarily driven by first quarter cash used in operating activities of approximately $28.0 million and partially offset by the receipt of $11.7 million from sales of common stock under our Cantor agreement. At March 31, 2018, Celldex had 143.4 million shares outstanding.
Revenues: Total revenue was $4.1 million in the first quarter of 2018, compared to $1.5 million for the comparable period in 2017. The increase in revenue was primarily due to the contract manufacturing and research and development agreements with International AIDS Vaccine Initiative and Frontier Biotechnologies, Inc. signed in the second quarter of 2017.
R&D Expenses: Research and development (R&D) expenses were $21.9 million in the first quarter of 2018, compared to $25.8 million for the comparable period in 2017. The decrease in R&D expenses was primarily due to lower varlilumab, CDX-3379 and anti-KIT program product development expenses of $0.9 million, $0.7 million and $0.3 million, respectively, and lower personnel and facility costs of $1.4 million.
G&A Expenses: General and administrative (G&A) expenses were $5.6 million in the first quarter of 2018, compared to $7.2 million for the comparable period in 2017. The decrease in G&A expenses was primarily due to lower personnel expenses of $0.7 million, lower commercial planning costs of $0.4 million and lower legal, consulting and professional services expense of $0.3 million.
Changes in Fair Value Remeasurement of Contingent Consideration: The $13.6 million gain on the fair value remeasurement of contingent consideration in the first quarter of 2018 was primarily due to updated assumptions for glemba-related milestones and discount rates. The $3.4 million loss on fair value remeasurement of contingent consideration in the first quarter of 2017 was primarily due to changes in discount rates and the passage of time.
Intangible Asset and Goodwill Impairments: The Company recorded $18.7 million in non-cash impairment charges related to fully impaired glemba-related intangible assets and $91.0 million in goodwill impairment charges as the carrying value of the Company’s net assets exceeded the Company’s fair value by an amount in excess of the goodwill asset in the first quarter of 2018.
Income Tax Benefit: The Company recorded a $0.8 million non-cash income tax benefit related to the impaired glemba in-process research and development (IPR&D) assets in the first quarter of 2018.
Net Loss: Net loss was $118.1 million, or ($0.84) per share, for the first quarter of 2018, compared to a net loss of $34.3 million, or ($0.28) per share, for the comparable period in 2017.
Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2018, combined with the anticipated proceeds from future sales of our common stock under the Cantor agreement, are sufficient to meet estimated working capital requirements and fund planned operations through 2020. This could be impacted if Celldex elects to pay Kolltan contingent milestones, if any, in cash.
Opdivo® is a registered trademark of Bristol-Myers Squibb. Erbitux® is a registered trademark of Eli Lilly & Co.
About Celldex Therapeutics, Inc.Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Forward Looking StatementThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to realize the anticipated benefits from the acquisition of Kolltan and to operate the combined business efficiently; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
CELLDEX THERAPEUTICS, INC. | |||||||||
(In thousands, except per share amounts) | |||||||||
CONSOLIDATED STATEMENTS | Three Months | ||||||||
OF OPERATIONS DATA | Ended March 31, | ||||||||
2018 | 2017 | ||||||||
REVENUES: | |||||||||
Product Development and | |||||||||
Licensing Agreements | $ | 992 | $ | 556 | |||||
Contracts and Grants | 3,076 | 978 | |||||||
Total Revenue | 4,068 | 1,534 | |||||||
OPERATING EXPENSES: | |||||||||
Research and Development | 21,875 | 25,793 | |||||||
General and Administrative | 5,593 | 7,229 | |||||||
Goodwill Impairment | 90,976 | - | |||||||
Intangible Asset Impairment | 18,677 | - | |||||||
(Gain)/Loss on Fair Value Remeasurement | |||||||||
of Contingent Consideration | (13,600 | ) | 3,400 | ||||||
Amortization of Acquired Intangible Assets | 224 | 224 | |||||||
Total Operating Expense | 123,745 | 36,646 | |||||||
Operating Loss | (119,677 | ) | (35,112 | ) | |||||
Investment and Other Income, Net | 780 | 851 | |||||||
Net Loss Before Income Tax Benefit | (118,897 | ) | (34,261 | ) | |||||
Income Tax Benefit | 765 | - | |||||||
Net Loss | $ | (118,132 | ) | $ | (34,261 | ) | |||
Basic and Diluted Net Loss per | |||||||||
Common Share | $ | (0.84 | ) | $ | (0.28 | ) | |||
Shares Used in Calculating Basic | |||||||||
and Diluted Net Loss per Share | 140,548 | 122,648 | |||||||
CONDENSED CONSOLIDATED | |||||||||
BALANCE SHEETS DATA | March 31, | December 31, | |||||||
2018 | 2017 | ||||||||
ASSETS | |||||||||
Cash, Cash Equivalents and Marketable Securities | $ | 123,248 | $ | 139,427 | |||||
Other Current Assets | 7,724 | 5,329 | |||||||
Property and Equipment, net | 9,785 | 10,372 | |||||||
Intangible and Other Assets, net | 50,619 | 160,496 | |||||||
Total Assets | $ | 191,376 | $ | 315,624 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
Current Liabilities | $ | 24,012 | $ | 27,736 | |||||
Long-Term Liabilities | 33,282 | 51,519 | |||||||
Stockholders' Equity | 134,082 | 236,369 | |||||||
Total Liabilities and Stockholders' Equity | $ | 191,376 | $ | 315,624 | |||||
Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & AdministrationCelldex Therapeutics, Inc.(781) 433-3161scavanaugh@celldex.com
Charles LilesAssociate Director, Investor Relations & Corp CommunicationsCelldex Therapeutics, Inc.(617) 383-3433cliles@celldex.com
1 Year Celldex Therapeutics Chart |
1 Month Celldex Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions